title: Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics.
abstract: Hypertriglyceridemia is a frequent and heterogeneous clinical trait, which modulates the risk of disease. Fibrates constitute an effective class of triglyceride-lowering agents.
  
  
  OBJECTIVE
  To evaluate the effect of fibrates on fasting plasma triglycerides and other lipids levels in hypertriglyceridemia phenotypes with different genetic and clinical characteristics.
  
  
  METHODS
  This study included 146 fasting adults: 15 with lactescent plasma and severe hypertriglyceridemia (triglyceride ≥ 10 mmol/l) and 131 with clear plasma and moderate hypertriglyceridemia (2 ≤ triglycerides <10 mmol/l). Expost comparisons of the effect of fibrates on fasting triglycerides and other lipids were made using Student's paired two-tailed t-test.
  
  
  RESULTS
  Response to these fibrates differed significantly across the studied hypertriglyceridemia subtypes: patients with severe hypertriglyceridemia because of lipoprotein lipase deficiency and those with moderate hypertriglyceridemia because of glycerol kinase deficiency did not respond at all, whereas patients with palmar xanthomas and severe or moderate hypertriglyceridemia because of apolipoprotein (apo) E resistance (type-III dysbetalipoproteinemia, most often associated with the apo E2 allele) responded significantly better (P<0.001) than all other subtypes on several lipid fractions.
  
  
  CONCLUSIONS
  These results indicate that genetic factors known to contribute to the etiology and clinical expression of hypertriglyceridemia subtypes also modulate the response to triglyceride-lowering drugs.
authors.affiliation: Department of Medicine, Université de Montréal, ECOGENE-21 and Lipid Clinic, Chicoutimi Hospital, Saguenay, Quebec, Canada.
authors.forename: Diane
authors.initials: D
authors.lastname: Brisson
authors.forename: Julie
authors.initials: J
authors.lastname: Méthot
authors.forename: Karine
authors.initials: K
authors.lastname: Tremblay
authors.forename: Monique
authors.initials: M
authors.lastname: Tremblay
authors.forename: Patrice
authors.initials: P
authors.lastname: Perron
authors.forename: Daniel
authors.initials: D
authors.lastname: Gaudet
mesh_terms: D000328:Adult; D008076:Cholesterol, HDL / Q000097:blood; D005260:Female; D058607:Fibric Acids / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008297:Male; D010641:Phenotype; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D058607:Fibric Acids; D014280:Triglycerides